Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab + Sargramostim in Recurrent Osteosarcoma
NCT02484443Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of dinutuximab in osteosarcoma (OS), sponsored by National Cancer Institute. Started Feb 2016; status: completed.
02
Drugs
dinutuximab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02484443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484443.